Skip to main content

Expert Insights

C. Ola Landgren, MD, PhD
Videos
03/21/2025
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares...
03/21/2025
Oncology
Matthew Powell, MD
Conference Coverage
03/20/2025
Matthew Powell, MD, discusses results from the KEYLINK-001 study which demonstrated that the addition of pembrolizumab and olaparib to standard therapy improved progression-free survival among patients with advanced BRCA non-mutated...
Matthew Powell, MD, discusses results from the KEYLINK-001 study which demonstrated that the addition of pembrolizumab and olaparib to standard therapy improved progression-free survival among patients with advanced BRCA non-mutated...
Matthew Powell, MD, discusses...
03/20/2025
Oncology
Allison Brodsky, MD
Conference Coverage
03/20/2025
Allison Brodsky, MD, discusses translational results from the phase 1b COPANIRA trial which assessed the relationship between molecular profiling and response to copanlisib and niraparib among patients with recurrent ovarian and endometrial...
Allison Brodsky, MD, discusses translational results from the phase 1b COPANIRA trial which assessed the relationship between molecular profiling and response to copanlisib and niraparib among patients with recurrent ovarian and endometrial...
Allison Brodsky, MD, discusses...
03/20/2025
Oncology
Toon Van Gorp, MD, PhD, University Hospital Leuven
Videos
03/17/2025
Dr Van Gorp shares insights on the final analysis of the MIRASOL trial evaluating mirvetuximab soravtansine among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer.
Dr Van Gorp shares insights on the final analysis of the MIRASOL trial evaluating mirvetuximab soravtansine among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer.
Dr Van Gorp shares insights on...
03/17/2025
Oncology
Michael Green, PhD
Conference Coverage
03/17/2025
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses...
03/17/2025
Oncology
Lori Wirth, MD, Massachusetts General Hospital
Videos
03/14/2025
Lori Wirth, MD, discusses the selpercatinib for advanced RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory differentiated thyroid cancer.
Lori Wirth, MD, discusses the selpercatinib for advanced RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory differentiated thyroid cancer.
Lori Wirth, MD, discusses the...
03/14/2025
Oncology
Neoadjuvant TKI to Downstage Unresectable DTC
Videos
03/14/2025
Mira Milas, MD, and Christian Nasr, MD, discuss the potential of neoadjuvant tyrosine kinase inhibition to downstage unresectable differentiated thyroid cancer.
Mira Milas, MD, and Christian Nasr, MD, discuss the potential of neoadjuvant tyrosine kinase inhibition to downstage unresectable differentiated thyroid cancer.
Mira Milas, MD, and Christian...
03/14/2025
Oncology
Neoadjuvant TKI to Downstage Unresectable DTC
Videos
03/14/2025
Mira Milas, MD, and Christian Nasr, MD, discuss the potential of neoadjuvant tyrosine kinase inhibition to downstage unresectable differentiated thyroid cancer.
Mira Milas, MD, and Christian Nasr, MD, discuss the potential of neoadjuvant tyrosine kinase inhibition to downstage unresectable differentiated thyroid cancer.
Mira Milas, MD, and Christian...
03/14/2025
Oncology
Laurence Albiges, MD, PhD, Gustave Roussy
Videos
03/13/2025
Laurence Albiges, MD, PhD, discusses the final results from the COSMIC-313 trial which evaluated cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.
Laurence Albiges, MD, PhD, discusses the final results from the COSMIC-313 trial which evaluated cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.
Laurence Albiges, MD, PhD,...
03/13/2025
Oncology
Laura Dawson, MD, Princess Margaret Cancer Care
Videos
03/11/2025
Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.
Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.
Laura Dawson, MD, discusses the...
03/11/2025
Oncology